Abstract 322P
Background
The COVID-19 pandemic has affected more than ten million people worldwide with nearly four lakh deaths. Cancer patients requiring continuum of care are facing difficulty accessing healthcare. Due to the risk of infection with COVID-19, their treatments have been rescheduled, elective procedures postponed, intravenous chemotherapies transitioned to oral medications, where possible, maintenance therapies deferred, and supportive care administered at home. Hence, we conducted a survey from the hospital patient registry to provide critical, up-to-date information about the impact of COVID-19 on cancer patients.
Methods
Patients taking treatment in the Department of Medical Oncology and Haematology at the American Oncology Institute, Hyderabad were given an online questionnaire upon consent. Details included age, cancer type, disease stage, treatment phase, delay in hospital appointment, procuring essential drugs including pain medicine, investigations, average time delay, impact on mental health, interpersonal relationships, deferring treatment due to fear of infection amongst other questions. Survey is also available in the local language besides English.
Results
A total of 200 patients participated in the survey with majority in the age group of 26-75 years (95.5%), 60% being female and the commonest cancers being breast (22%) and lung (16.5%) respectively. Patients receiving chemotherapy and immunotherapy were 58% and 3.9% with most being stage 3 (29%) and 4 (48.5%). Treatment delays were faced by 32% for various reasons while mental health impact in 67% patients. Majority of the patients expressed being at higher risk from COVID-19, with 35.8% agreeing upon continuation of chemotherapy and 66% preferring transition from injectable to oral medication. Forty five percent were aware of COVID-19 prophylaxis, while 85% discussed continuation or deferring treatment with their respective care giver.
Conclusions
This survey was a cooperative effort across many physicians, nurses and patients to provide critical, up-to-date information about the impact of the COVID-19 pandemic on cancer patients. Completing this short 10-minute survey or questionnaire will help health care to identify COVID-19 related issues in the community.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
163P - Gastrointestinal stromal tumours (GIST) in adolescents and young adults (AYA) in an Asian institution from 2002 to 2018
Presenter: Evelyn Yi Ting Wong
Session: e-Poster Display Session
164P - The impact of sarcopenia on chemotherapy toxicity and survival rate among hepatocellular carcinoma patients who underwent chemotherapy: A systematic review and meta-analysis
Presenter: Elizabeth Marcella
Session: e-Poster Display Session
165P - Prognostic factors in sorafenib-treated hepatocellular carcinoma: Multicentre analysis of a European population sample
Presenter: João Gramaça
Session: e-Poster Display Session
166P - Differences and similarities in presentation and management patterns in patients with hepatocellular carcinoma (HCC) across Hong Kong, Singapore and Thailand
Presenter: Pierce Chow
Session: e-Poster Display Session
167P - Epidemiology of hepatocellular carcinoma (HCC) in tertiary level hospitals in Bangladesh
Presenter: Abdullah Al Mamun Khan
Session: e-Poster Display Session
168P - Response assessments in hepatocellular carcinoma: What are the best criteria to utilize? mRECIST or RECIST 1.1? A retrospective meta-analysis of multiple phase III trials
Presenter: Oliver Bohnsack
Session: e-Poster Display Session
169P - IMbrave150: Management of adverse events of special interest (AESIs) for atezolizumab (atezo) and bevacizumab (bev) in unresectable HCC
Presenter: Masatoshi Kudo
Session: e-Poster Display Session
170P - Sintilimab plus anlotinib as first-line therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC)
Presenter: Xiaofeng Chen
Session: e-Poster Display Session
171P - Transarterial chemoembolization (TACE) plus lenvatinib versus TACE plus sorafenib for hepatocellular carcinoma (HCC) with portal vein tumour thrombus (PVTT): A prospective randomized study
Presenter: Xiaoyan Ding
Session: e-Poster Display Session
172P - Triple combination therapy of lenvatinib, toripalimab, and hepatic arterial infusion chemotherapy versus lenvatinib for advanced hepatocellular carcinoma
Presenter: Zhi-Cheng Lai
Session: e-Poster Display Session